Pfizer Curtails Development Deals For Pulmonary Drug, HIV Therapy
This article was originally published in The Pink Sheet Daily
Altana says it will continue to develop Daxas for chronic obstructive pulmonary disease and asthma independently after Pfizer pulls out of the collaboration. One-year data failed to meet one primary endpoint. Pfizer also ends a development pact with Shionogi for the HIV/AIDS agent capravirine.
You may also be interested in...
Altana has withdrawn the European marketing authorization application for its pulmonary agent Daxas (roflumilast), the firm announced Nov. 15
Roche will consider requesting a re-examination of the negative decision by the Committee for Medicinal Products for Human Use.